Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given an average rating of “Moderate Buy” by the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $22.57.

A number of analysts have issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. JPMorgan Chase & Co. boosted their price target on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, March 28th.

Neumora Therapeutics Stock Up 1.0 %

NMRA opened at $9.15 on Friday. The company has a fifty day moving average of $14.64 and a 200 day moving average of $14.07. Neumora Therapeutics has a fifty-two week low of $8.82 and a fifty-two week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.05. Sell-side analysts predict that Neumora Therapeutics will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Addis & Hill Inc bought a new stake in shares of Neumora Therapeutics in the 1st quarter worth about $4,187,000. Windmill Hill Asset Management Ltd purchased a new stake in Neumora Therapeutics in the 1st quarter worth about $359,000. Avidity Partners Management LP lifted its stake in Neumora Therapeutics by 10.6% in the fourth quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company’s stock worth $33,940,000 after purchasing an additional 190,632 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $44,000. Finally, Amalgamated Bank bought a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $29,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.